bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.90 USD
+0.01 (0.87%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.90 0.00 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 521 - 532 ( 532 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Phase I/II Data in Beta-Thal Suggests Potential for Improved Clinical Outcomes with LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Phase I/II Data in Beta-Thal Suggests Potential for Improved Clinical Outcomes with LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q1:14, Initial Results of LentiGlobin in Beta-Thal at Upcoming Scientific Meeting, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Beta-Thal Patient Enrolled in US Study of LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Beta-Thal Patient Enrolled in US Study of LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
2013 Year-End Results, Well-capitalized, with Programs on Track, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in Beta-thal Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in Beta-thal Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q3:13 EPS: Beginning Pivotal Studies; Well- Capitalized, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Enrolled in CCALD Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at OUTPERFORM with a $40 Price Target: BLUE: Gene Therapy Is Back and BLUE
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D